CG Oncology, Inc.

CGON Nasdaq SEC CIK 1991792
Follow CG Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.6M −3.7% vs same quarter last year
Net income −$56.9M −29.9% vs same quarter last year
EPS, diluted −$0.64 −12.3% vs same quarter last year
Operating cash flow −$47.7M −22.7% vs same quarter last year
Revenue by quarter
$456K
$52K
$0
$1.7M
$2.3M
$1.1M
$1.2M
$1.6M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$200M−$150M−$100M−$50M$0$50MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$4M−$161M
FY24$1.1M−$88M
FY23$204K−$48.6M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−30000%−20000%−10000%0%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−4722.1%−3985.1%
FY24−10067.3%−7729.6%
FY23−27180.9%−23827%
FY22--
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • CG Oncology
  • Healthcare median
−30000%−20000%−10000%0%FY22FY23FY24FY25
Show the numbers
YearCG OncologyHealthcare median
FY25−3985.1%−30.6%
FY24−7729.6%−47%
FY23−23827%−58%
FY22-−80.4%